Results 21 to 30 of about 546 (157)
Clinical and Translational SciencePenetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood–brain barrier, which is the most ...
Marin Lahouati +5 more
doaj +2 more sources
Biomédica: revista del Instituto Nacional de Salud, 2018 Introducción. Staphylococcus aureus resistente a meticilina (SARM) causa infecciones graves de la piel y los tejidos blandos en los hospitales y, en los últimos años, en la comunidad.
Aura Lucía Leal +9 more
doaj +3 more sources
Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
Drug Design, Development and Therapy, 2016 Olivia Ferrández,1,2 Olatz Urbina,1 Santiago Grau1,3 1Hospital Pharmacy, Hospital Universitari del Mar, Barcelona, Spain; 2Nursing Department, Universitat Pompeu Fabra, Barcelona, Spain; 3Medicine Department, Universitat Autònoma de ...
Ferrández O, Urbina O, Grau S
doaj +1 more source
Therapeutics and Clinical Risk Management, 2015 Michael J Durkin,1 G Ralph Corey2,3 1Department of Medicine, Division of Infectious Diseases, Duke University, Durham, NC, USA; 2Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA; 3Duke Global Health Institute, Durham ...
Durkin MJ, Corey GR
doaj +2 more sources
Амбулаторная хирургия, 2019 The work describes a new antibiotic from the oxazolidinone group – tedizolid. The results of the clinical studies have shown a high efficacy of tedizolid in complicated skin and soft tissue infections.
A. V. Rodin, O. I. Agafonov
doaj +2 more sources
In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
Frontiers in Microbiology, 2018 Background:Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole.
Dana Binyamin +9 more
doaj +2 more sources
Safety and tolerability of tedizolid as oral treatment for bone and joint infections
Microbiology Spectrum, 2023 Bone and joint infections (BJIs) are common infections increasingly managed with oral therapy. However, there are limited safe oral options for many Gram-positive pathogens.
Loren G. Miller +10 more
doaj +1 more source
Tedizolid: new data and experiences for clinical practice [PDF]
Revista Española de Quimioterapia, 2021 The most relevant information on the clinical uses of tedizolid from studies published in the last 18 months is presented in this brief review. The most important data indicate better tolerance and safety profile of long-term therapeutic regimes in off-label indications, such as osteoarticular infections and those caused by mycobacteria. Its lower risk
Salavert Lleti, M +3 more
openaire +3 more sources
International Journal of Infectious Diseases, 2021 Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia.
Cecilia G. Carvalhaes +3 more
doaj +1 more source
Journal of Pharmaceutical Health Care and Sciences, 2023 Background Tedizolid is a new oxazolidinone antibiotic with high potency for the treatment of infections caused by methicillin-resistant Staphylococcus aureus and other species.
Daisuke Negishi +5 more
doaj +1 more source